Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
progression or deaths (PFS) | 0.60 [0.45, 0.80] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 1.57 [0.99, 2.50] | | > 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.26 [0.03, 2.38] | | < 1 | | 0% | 1 study (1/-) | 88.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.41 [0.25, 0.67] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.79 [0.26, 2.42] | | < 1 | | 0% | 1 study (1/-) | 65.8 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.14 [0.08, 0.23] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 3.77 [0.17, 84.42] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.26 [0.05, 1.26] | | < 1 | | 0% | 1 study (1/-) | 95.2 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.09 [0.00, 1.67] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 9.63 [0.52, 177.85] | | < 1 | | 0% | 1 study (1/-) | 6.6 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.18 [0.05, 0.66] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
Dizziness TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Epistaxis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.20 [0.06, 0.72] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 7.65 [0.40, 146.03] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 1.88 [0.17, 20.97] | | < 1 | | 0% | 1 study (1/-) | 30.5 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 2.84 [0.29, 27.62] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.07 [0.00, 1.35] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy TRAE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.93 [0.06, 15.08] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 0.93 [0.13, 6.72] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.07 [0.00, 1.35] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.09 [0.00, 1.67] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.93 [0.34, 2.55] | | < 1 | | 0% | 1 study (1/-) | 55.5 % | NA | not evaluable | | non important | - |
Alopecia AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.47 [0.19, 1.15] | | < 1 | | 0% | 1 study (1/-) | 95.1 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.46 [0.11, 1.86] | | < 1 | | 0% | 1 study (1/-) | 86.2 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 1.88 [0.17, 20.97] | | < 1 | | 0% | 1 study (1/-) | 30.5 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.06 [0.00, 1.13] | | < 1 | | 0% | 1 study (1/-) | 96.8 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.50 [0.21, 1.16] | | < 1 | | 0% | 1 study (1/-) | 94.7 % | NA | not evaluable | | non important | - |
Dizziness AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dry skin AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dyspepsia AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Epistaxis AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.41 [0.15, 1.10] | | < 1 | | 0% | 1 study (1/-) | 96.1 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 1.51 [0.57, 4.00] | | < 1 | | 0% | 1 study (1/-) | 20.6 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 0.93 [0.02, 47.41] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 1.25 [0.28, 5.70] | | < 1 | | 0% | 1 study (1/-) | 38.6 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 1.25 [0.28, 5.70] | | < 1 | | 0% | 1 study (1/-) | 38.6 % | NA | not evaluable | | non important | - |
Mucosal inflammation AE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.61 [0.17, 2.22] | | < 1 | | 0% | 1 study (1/-) | 77.2 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.02 [0.00, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Peripheral neuropathy AE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Peripheral oedema AE (grade 3-4) | 0.23 [0.01, 5.17] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy AE (grade 3-4) | 0.15 [0.01, 3.08] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.47 [0.02, 13.99] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 1.88 [0.06, 56.32] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.93 [0.06, 15.08] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
Stomatitis AE (grade 3-4) | 0.07 [0.00, 1.35] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.26 [0.05, 1.26] | | < 1 | | 0% | 1 study (1/-) | 95.2 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.93 [0.06, 15.08] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |